Cargando…

Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

BACKGROUND: Patients with isocitrate dehydrogenase (IDH) mutant gliomas have been associated with longer survival time than those that are IDH wild-type. Previous studies have shown the prognostic value of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation for glioblastoma multifor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lam, Keng, Eldred, Blaine S C, Kevan, Bryan, Pianka, Sean, Eldred, Brittany A, Zapanta Rinonos, Serendipity, Yong, William H, Liau, Linda M, Nghiemphu, Phioanh L, Cloughesy, Timothy F, Green, Richard M, Lai, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982195/ https://www.ncbi.nlm.nih.gov/pubmed/35386566 http://dx.doi.org/10.1093/noajnl/vdac030

Ejemplares similares

A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients
por: Liu, Vicki, et al.
Publicado: (2023)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Erratum to: Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
Publicado: (2022)

Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI
por: Hagiwara, Akifumi, et al.
Publicado: (2022)

The diagnostic value of ADC histogram and direct ADC measurements for coexisting isocitrate dehydrogenase mutation and O6-methylguanine-DNA methyltransferase promoter methylation in glioma
por: Xie, Zhiyan, et al.
Publicado: (2023)

Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience
por: Ji, Matthew S, et al.
Publicado: (2020)

O(6)-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma
por: Alassiri, Ali H., et al.
Publicado: (2019)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Prognostic value of isocitrate dehydrogenase 1, O(6)-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients
por: Takahashi, Yoshinobu, et al.
Publicado: (2013)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series
por: Liu, Liang Yen, et al.
Publicado: (2019)

Vorasidenib: A promising therapeutic breakthrough for diffuse isocitrate dehydrogenase mutant gliomas
por: Wahid, Abdul, et al.
Publicado: (2023)

Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma
por: Oshima, Sonoko, et al.
Publicado: (2023)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
por: Nghiemphu, Phioanh Leia, et al.
Publicado: (2012)

Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study
por: Yao, Jingwen, et al.
Publicado: (2020)

Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas
por: Kim, Ja Eun, et al.
Publicado: (2015)

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas
por: Beyer, Sasha J., et al.
Publicado: (2018)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
por: Golub, Danielle, et al.
Publicado: (2019)

BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI
por: Ellingson, Benjamin, et al.
Publicado: (2021)

5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
por: Glowacka, Wioletta K., et al.
Publicado: (2018)

Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report
por: Morimoto, Takayuki, et al.
Publicado: (2022)

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
por: OHBA, Shigeo, et al.
Publicado: (2016)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

O(6)-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy
por: Yu, Wei, et al.
Publicado: (2020)

Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma
por: Li, Xianqi, et al.
Publicado: (2022)

The Antiepileptic Drug Oxcarbazepine Inhibits the Growth of Patient-Derived Isocitrate Dehydrogenase Mutant Glioma Stem-like Cells
por: Dao Trong, Philip, et al.
Publicado: (2023)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
por: Tatekawa, Hiroyuki, et al.
Publicado: (2021)

O(6)-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas
por: Fan, C-H, et al.
Publicado: (2013)

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
por: Huang, Juan, et al.
Publicado: (2019)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials
por: Sharma, Nikhil, et al.
Publicado: (2023)

Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide
por: Tso, Jonathan L., et al.
Publicado: (2015)

Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
por: Dao Trong, P., et al.
Publicado: (2023)

O(6)-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies
por: Sasai, Ken, et al.
Publicado: (2007)

Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1
por: Kim, Hyo-Joon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0nf8gnfmvlnp2dh1uekrv03h5v